Oncology patients have been posting shocking confessions on social media for days, saying that they cannot receive treatment that means life or death for them because of a shortage of cytostatics.
The Clinical Center of the University of Sarajevo (KCUS) states that they are currently faced with the problem of shortages of certain drugs, as a result of which they are temporarily unable to provide continuous therapy to oncology patients.
“KCUS is doing everything in our power to solve this problem. We note that KCUS does not procure cytostatic drugs, but the procurement and payment of these, usually extremely expensive and rare drugs, is the responsibility of the Federal Health Insurance and Reinsurance Fund of FBiH”, they point out.
Based on the request of clinics applying oncology drugs, the KCUS clinical pharmacy submits the need for cytostatics to the Institute of Health Insurance and Reinsurance of FBiH, which is responsible for the procurement of cytostatics itself.
Manufacturers and suppliers of cytostatics often have a shortage of drugs on the global market and, therefore, late delivery to FBiH, and consequently also to KCUS.
“We also want to emphasize that negotiations and expert consultations are being conducted simultaneously regarding the problems of the health system, especially the problems of procurement of drugs and cytostatics, in order to systematically solve it,” they concluded, Klix.ba writes.
